CN1839865A - 抗肿瘤的黄芩甙元和黄芩甙协同药物组合物 - Google Patents
抗肿瘤的黄芩甙元和黄芩甙协同药物组合物 Download PDFInfo
- Publication number
- CN1839865A CN1839865A CN 200610006555 CN200610006555A CN1839865A CN 1839865 A CN1839865 A CN 1839865A CN 200610006555 CN200610006555 CN 200610006555 CN 200610006555 A CN200610006555 A CN 200610006555A CN 1839865 A CN1839865 A CN 1839865A
- Authority
- CN
- China
- Prior art keywords
- yellow
- baicalin
- wild
- huang
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 16
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 title abstract description 3
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 title abstract description 3
- 229940015301 baicalein Drugs 0.000 title abstract description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 title description 104
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 title description 102
- 229960003321 baicalin Drugs 0.000 title description 102
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 title description 102
- 230000000118 anti-neoplastic effect Effects 0.000 title description 4
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 208000032839 leukemia Diseases 0.000 claims description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 5
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 201000008275 breast carcinoma Diseases 0.000 claims description 4
- YVECGMZCTULTIS-PBXRRBTRSA-N glucal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@@H]1O YVECGMZCTULTIS-PBXRRBTRSA-N 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000001514 prostate carcinoma Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 125000002367 glucuronosyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 80
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 78
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 78
- 229930190376 scutellarin Natural products 0.000 description 78
- 230000000694 effects Effects 0.000 description 57
- 210000000683 abdominal cavity Anatomy 0.000 description 37
- 239000003814 drug Substances 0.000 description 37
- 241001465754 Metazoa Species 0.000 description 32
- 238000012360 testing method Methods 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 22
- 239000000890 drug combination Substances 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 21
- 150000002338 glycosides Chemical class 0.000 description 20
- 229940079593 drug Drugs 0.000 description 17
- 150000008131 glucosides Chemical class 0.000 description 16
- 229930182470 glycoside Natural products 0.000 description 16
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 16
- 230000010261 cell growth Effects 0.000 description 15
- 229930182478 glucoside Natural products 0.000 description 13
- -1 flavone compound Chemical class 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 229930003944 flavone Natural products 0.000 description 6
- 235000011949 flavones Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004534 Scutellaria baicalensis Species 0.000 description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000008121 plant development Effects 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WYTRYIUQUDTGSX-UHFFFAOYSA-N 1-phenylpropan-2-ol Chemical compound CC(O)CC1=CC=CC=C1 WYTRYIUQUDTGSX-UHFFFAOYSA-N 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 206010018404 Glucagonoma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 7.4±2 | ||
黄元5 | 34.93±3 | ||
黄元10 | 50.2±3 | ||
黄元20 | 58.5±2.5 | ||
黄元40 | 89.18±2 | ||
黄芩甙2.5 | 16.63±2 | ||
黄芩甙5 | 16.8±2 | ||
黄芩甙10 | 34.93±3.8 | ||
黄芩甙20 | 50±2.9 | ||
黄芩甙40 | 86.69±3 | ||
1∶1 | 黄元5+黄5 | 45±5 | 0.95 |
黄元10+黄10 | 70±3 | 0.88 | |
黄元20+黄20 | 97.5±3 | 0.228 | |
1∶2 | 黄元2.5+黄5 | 9.64±1 | 3.26 |
黄元5+黄10 | 66.1±3 | 0.7143 | |
黄元10+黄20 | 80.9±2 | 0.7961 | |
黄元20+黄40 | 92.3±2 | 0.7299 | |
1∶4 | 黄元2.5+黄10 | 38.43±3 | 1.379 |
黄元5+黄20 | 83.2±2 | 0.5542 | |
黄元10+黄40 | 91.7±2.1 | 0.5965 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 5.8±2 | ||
黄元5 | 20.5±3 |
黄元10 | 29.2±3 | ||
黄元20 | 41±2.7 | ||
黄元40 | 89.15±3 | ||
黄芩甙2.5 | 17±2 | ||
黄芩甙5 | 20±3.2 | ||
黄芩甙10 | 27±3 | ||
黄芩甙20 | 33.75±3 | ||
黄芩甙40 | 90±2 | ||
1∶1 | 黄元5+黄5 | 32.25±3 | 1.15 |
黄元10+黄10 | 63.45±3.2 | 0.88 | |
黄元20+黄20 | 95±1 | 0.31 | |
1∶2 | 黄元2.5+黄5 | 12.8±3.7 | 2.22 |
黄元5+黄10 | 35.9±3 | 1.56 | |
黄元10+黄20 | 72.5±3 | 0.94 | |
黄元20+黄40 | 97±1 | 0.285 | |
1∶4 | 黄元2.5+黄10 | 29.2±2.9 | 1.68 |
黄元5+黄20 | 60.62±3 | 1.17 | |
黄元10+黄40 | 96.71±2.1 | 0.2322 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 13.5±4 | ||
黄元5 | 17.18±3 | ||
黄元10 | 39.2±2 | ||
黄元20 | 63.85±3.2 | ||
黄元40 | 96.41±2 | ||
黄芩甙2.5 | 9.8±2 | ||
黄芩甙5 | 17±3 | ||
黄芩甙10 | 30.58±3.2 |
黄芩甙20 | 53.58±4 | ||
黄芩甙40 | 92±3 | ||
1∶1 | 黄元5+黄5 | 58±2 | 0.734 |
黄元10+黄10 | 85.5±2 | 0.626 | |
黄元20+黄20 | 98±3 | 0.364 | |
1∶2 | 黄元2.5+黄5 | 15.8±3 | 1.742 |
黄元5+黄10 | 78.3±2.2 | 0.54 | |
黄元10+黄20 | 86.03±1.95 | 0.8588 | |
黄元20+黄40 | 96.5±1 | 0.702 | |
1∶4 | 黄元2.5+黄10 | 49.55±2 | 0.9 |
黄元5+黄20 | 96.03±1 | 0.295 | |
黄元10+黄40 | 97.2±1 | 0.457 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 7.7±3 | ||
黄元5 | 37.11±2.9 | ||
黄元10 | 53±3.2 | ||
黄元20 | 58±2 | ||
黄元40 | 77±3 | ||
黄芩甙2.5 | 5.2±2 | ||
黄芩甙5 | 12±3 | ||
黄芩甙10 | 30.2±2.9 | ||
黄芩甙20 | 62±3.2 | ||
黄芩甙40 | 85.22±2 | ||
1∶1 | 黄元5+黄5 | 41±3 | 0.95 |
黄元10+黄10 | 67.8±2.2 | 0.853 | |
黄元20+黄20 | 85.7±2.3 | 0.815 | |
1∶2 | 黄元2.5+黄5 | 12±3 | 2.13 |
黄元5+黄10 | 35.2±5 | 1.61 | |
黄元10+黄20 | 76.5±2.5 | 0.95 | |
黄元20+黄40 | 93±2 | 0.76 | |
1∶4 | 黄元2.5+黄10 | 25±3 | 1.76 |
黄元5+黄20 | 70.7±3 | 0.98 | |
黄元10+黄40 | 95±2 | 0.536 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 5.5±1 | ||
黄元5 | 17.2±2.8 | ||
黄元10 | 28±2 | ||
黄元20 | 57.9±2.1 | ||
黄元40 | 85.2±2.3 | ||
黄芩甙2.5 | 6.2±1.8 | ||
黄芩甙5 | 12±3 | ||
黄芩甙10 | 28.2±2.5 | ||
黄芩甙20 | 49.8±1.78 | ||
黄芩甙40 | 72.7±2.1 | ||
1∶1 | 黄元5+黄5 | 18.7±2.3 | 1.57 |
黄元10+黄10 | 47.1±2.9 | 1.259 | |
黄元20+黄20 | 81.2±2 | 0.87 | |
1∶2 | 黄元2.5+黄5 | 10.1±2 | 1.91 |
黄元5+黄10 | 29.12±2.1 | 1.545 | |
黄元10+黄20 | 65.31±3 | 0.85 | |
黄元20+黄40 | 92±3 | 0.617 | |
1∶4 | 黄元2.5+黄10 | 7.8±1 | 3.89 |
黄元5+黄20 | 59±3 | 0.99 | |
黄元10+黄40 | 93±2 | 0.428 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 7.2±2 | ||
黄元5 | 27.55±2 | ||
黄元10 | 51±3 | ||
黄元20 | 71.77±2.5 | ||
黄元40 | 90.5±2.5 | ||
黄芩甙2.5 | 0.5±2.7 | ||
黄芩甙5 | 10.2±1 | ||
黄芩甙10 | 48.02±2 | ||
黄芩甙20 | 60.35±3 | ||
黄芩甙40 | 90±2 | ||
1∶1 | 黄元5+黄5 | 56.04±3 | 0.725 |
黄元10+黄10 | 88.95±2 | 0.573 | |
黄元20+黄20 | 95.53±1 | 0.711 | |
1∶2 | 黄元2.5+黄5 | 49.43±2 | 0.587 |
黄元5+黄10 | 80±2 | 0.6 | |
黄元10+黄20 | 91.5±1.5 | 0.762 | |
黄元20+黄40 | 97.7±1 | 0.82 | |
1∶4 | 黄元2.5+黄10 | 68.28±2.22 | 0.6529 |
黄元5+黄20 | 89.4±1 | 0.78 | |
黄元10+黄40 | 97±1 | 0.8 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 7.2±5 | ||
黄元5 | 22.8±6 | ||
黄元10 | 50.9±5 | ||
黄元20 | 69.9±5 |
黄元40 | 92.9±7 | ||
黄芩甙2.5 | 1±3 | ||
黄芩甙5 | 17.9±5 | ||
黄芩甙10 | 47±8 | ||
黄芩甙20 | 62±7 | ||
黄芩甙40 | 88±7 | ||
1∶1 | 黄元5+黄5 | 47.9±5 | 0.87 |
黄元10+黄10 | 77±3 | 0.89 | |
黄元20+黄20 | 92±5 | 0.95 | |
1∶2 | 黄元2.5+黄5 | 45±3 | 0.66 |
黄元5+黄10 | 72.8±5 | 0.73 | |
黄元10+黄20 | 87±3 | 0.92 | |
黄元20+黄40 | 95±5 | 1.1 | |
1∶4 | 黄元2.5+黄10 | 55.8±6 | 0.85 |
黄元5+黄20 | 77.9±5 | 1 | |
黄元10+黄40 | 97±5 | 0.72 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 6.5±2 | ||
黄元5 | 21.8±3 | ||
黄元10 | 41.32±2.7 | ||
黄元20 | 67.6±3.2 | ||
黄元40 | 86.77±3.3 | ||
黄芩甙2.5 | 5±2 | ||
黄芩甙5 | 8.6±3 | ||
黄芩甙10 | 21±4 | ||
黄芩甙20 | 45.1±2.9 | ||
黄芩甙40 | 82.7±2.3 |
1∶1 | 黄元5+黄5 | 43.13±3.23 | 0.79 |
黄元10+黄10 | 76.2±3 | 0.645 | |
黄元20+黄20 | 95±2 | 0.426 | |
1∶2 | 黄元2.5+黄5 | 10±2.5 | 1.81 |
黄元5+黄10 | 76.5±3 | 0.4445 | |
黄元10+黄20 | 85.2±2 | 0.62 | |
黄元20+黄40 | 95±2 | 0.59 | |
1∶4 | 黄元2.5+黄10 | 40.05±3 | 0.929 |
黄元5+黄20 | 78±2 | 0.66 | |
黄元10+黄40 | 95±3 | 0.465 |
分组 | 剂量mg/kg | 给药日程 | 体重减少率% | 瘤重(g)均值±SD, | 抑瘤率% | 动物数(只)始/末 |
对照组黄元黄甙黄甙 | -302550 | 腹腔1-10腹腔1-10腹腔1-10 | <0<5<5<5 | 2.18±0.151.72±0.091.81±0.11.77±0.117 | 21.116.9718.8 | 10/1010/1010/1010/10 |
黄甙黄甙黄元+黄甙黄元+黄甙黄元+黄甙黄元+黄甙5-氟脲嘧啶 | 10020030+2530+5030+10030+20010 | 腹腔1-10腹腔1-10各腹腔1-10各腹腔1-10各腹腔1-10各腹腔1-10皮下1-10 | <5<5<5<5<5<5<5 | 1.51±0.111.28±0.071.65±0.091.58±0.091.29±0.11.11±0.111.35±0.1 | 30.741.2824.3*#27.5**#40.8**#49**#38 | 10/1010/1010/1010/1010/1010/1010/10 |
分组 | 剂量mg/kg | 给药日程 | ILS(%) | 动物数(只)始/末 |
对照组黄元黄甙黄甙黄甙黄甙黄元+黄甙黄元+黄甙黄元+黄甙黄元+黄甙5-氟脲嘧啶 | -30255010020030+2530+5030+10030+20010 | 腹腔1-10腹腔1-10腹腔1-10腹腔1-10腹腔1-10各腹腔1-10各腹腔1-10各腹腔1-10各腹腔1-10皮下1-10 | 31.617.327.5538.275037.2*#47.9**#55.1**#67**#79 | 10/1010/1010/1010/1010/1010/1010/1010/1010/1010/1010/10 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 7.35±2.2 | ||
黄元5 | 32.7±2.3 | ||
黄元10 | 49.8±2.1 | ||
黄元20 | 58.5±1.2 | ||
黄元40 | 90.18±2.5 | ||
野黄芩甙2.5 | 5.2±2.1 | ||
野黄芩甙5 | 7.7±2.3 | ||
野黄芩甙10 | 43.35±2.7 | ||
野黄芩甙20 | 86.1±2.9 | ||
野黄芩甙40 | 88.45±2.5 | ||
黄元5+野黄5 | 70.1±2.2 | 0.537 | |
黄元10+野黄10 | 85.2±2.5 | 0.647 | |
黄元20+野黄20 | 92.77±3 | 0.82 |
黄元40+野黄40 | 97±3 | 0.987 | |
黄元2.5+野黄5 | 52.9±2 | 0.6 | |
黄元5+野黄10 | 88.12±2.1 | 0.438 | |
黄元10+野黄20 | 96.32±3.5 | 0.448 | |
黄元20+野黄40 | 98±3 | 0.64 | |
黄元2.5+野黄10 | 70.1±3 | 0.68 | |
黄元5+野黄20 | 87.7±2.2 | 0.768 | |
黄元10+野黄40 | 97±2.1 | 0.7 | |
黄元20+野黄80 | 99±2 | 0.8 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 5.8±2 | ||
黄元5 | 10.5±2.3 | ||
黄元10 | 29.2±2.7 | ||
黄元20 | 47±3.1 | ||
黄元40 | 91.15±2.5 | ||
野黄芩甙2.5 | 10.05±2.5 | ||
野黄芩甙5 | 15.1±3 | ||
野黄芩甙10 | 49±2.2 | ||
野黄芩甙20 | 83.7±2.2 | ||
野黄芩甙40 | 95±2.8 | ||
黄元5+野黄5 | 69.5±1.9 | 0.559 | |
黄元10+野黄10 | 87.2±2.3 | 0.627 | |
黄元20+野黄20 | 96±2.2 | 0.646 | |
黄元40+野黄40 | 98.7±2.1 | 0.88 | |
黄元2.5+野黄5 | 55±3 | 0.63 | |
黄元5+野黄10 | 85.7±3.2 | 0.55 | |
黄元10+野黄20 | 95±3.1 | 0.6 |
黄元20+野黄40 | 98.2±2.7 | 0.7 | |
黄元2.5+野黄10 | 75.78±3.2 | 0.68 | |
黄元5+野黄20 | 91.2±2.3 | 0.738 | |
黄元10+野黄40 | 97±2.1 | 0.822 | |
黄元20+野黄80 | 99±2 | 0.92 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 10.55±1.2 | ||
黄元5 | 17.19±2.2 | ||
黄元10 | 40.8±3.2 | ||
黄元20 | 62.5±2 | ||
黄元40 | 90.18±2.1 | ||
黄芩甙2.5 | 1±2.1 | ||
野黄芩甙5 | 7.7±3.3 | ||
野黄芩甙10 | 32.33±2.7 | ||
野黄芩甙20 | 62.65±2.5 | ||
野黄芩甙40 | 91±2.7 | ||
黄元5+野黄5 | 67.15±2.1 | 0.512 | |
黄元10+野黄10 | 83.2±2.2 | 0.64 | |
黄元20+野黄20 | 95±3.5 | 0.65 | |
黄元40+野黄40 | 98±1.2 | 0.8 | |
黄元2.5+野黄5 | 54.5±2 | 0.49 | |
黄元5+野黄10 | 86.2±2.2 | 0.44 | |
黄元10+野黄20 | 95.1±2.5 | 0.516 | |
黄元20+野黄40 | 98.5±2 | 0.587 | |
黄元2.5+野黄10 | 77±3 | 0.5 | |
黄元5+野黄20 | 90.2±1.5 | 0.632 | |
黄元10+野黄40 | 97±2 | 0.723 |
黄元20+野黄80 | 99±2 | 0.88 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 16.5±1.1 | ||
黄元5 | 27.7±2.1 | ||
黄元10 | 42.8±2.3 | ||
黄元20 | 65.6±3 | ||
元40 | 80.21±2.5 | ||
野黄芩甙2.5 | 18.83±2.2 | ||
野黄芩甙5 | 21.23±3.5 | ||
野黄芩甙10 | 31.65±2.8 | ||
野黄芩甙20 | 35.34±2.8 | ||
野黄芩甙40 | 75.34±2.7 | ||
黄元5+野黄5 | 55±1.7 | 0.55 | |
黄元10+野黄10 | 69±2.5 | 0.607 | |
黄元20+野黄20 | 79±3.1 | 0.722 | |
黄元40+野黄40 | 90±2.2 | 0.615 | |
黄元2.5+野黄5 | 44.9±2.2 | 0.57 | |
黄元5+野黄10 | 65.2±3.1 | 0.476 | |
黄元10+野黄20 | 71.62±1.2 | 0.699 | |
黄元20+野黄40 | 87±2 | 0.5 | |
黄元2.5+野黄10 | 63.5±3.2 | 0.3842 | |
黄元5+野黄20 | 69.35±2.2 | 0.573 | |
黄元10+野黄40 | 78.7±3 | 0.683 | |
黄元20+野黄80 | 87±3 | 0.725 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 5±2 | ||
黄元5 | 16.8±1.2 | ||
黄元10 | 38.4±2.1 | ||
黄元20 | 66.85±2 | ||
黄元40 | 83.1±2.1 | ||
野黄芩甙2.5 | 4.7±2.2 | ||
野黄芩甙5 | 12.97±3.1 | ||
野黄芩甙10 | 27.1±2.7 | ||
野黄芩甙20 | 66±2.9 | ||
野黄芩甙40 | 84.62±2.5 | ||
黄元5+野黄5 | 22.1±2.1 | 1.46 | |
黄元10+野黄10 | 51.67±2.3 | 1.33 | |
黄元20+野黄20 | 85.7±2.1 | 0.956 | |
黄元40+野黄40 | 97±2.5 | 0.7 | |
黄元2.5+野黄5 | 19.2±3 | 1.2 | |
黄元5+野黄10 | 47.7±2.3 | 1 | |
黄元10+野黄20 | 75.62±2.2 | 0.99 | |
黄元20+野黄40 | 92±3 | 0.97 | |
黄元2.5+野黄10 | 48.6±3 | 0.87 | |
黄元5+野黄20 | 77.33±2.2 | 0.826 | |
黄元10+野黄40 | 89.7±3 | 0.9559 | |
黄元20+野黄80 | 98.5±2 | 0.588 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 0.8±2 | ||
黄元5 | 13.02±2.5 | ||
黄元10 | 51.02±2.2 | ||
黄元20 | 64.35±2.2 |
黄元40 | 93±2.5 | ||
野黄芩甙2.5 | 5±2.5 | ||
野黄芩甙5 | 20.71±3.2 | ||
野黄芩甙10 | 71±2.2 | ||
野黄芩甙20 | 87.5±2.5 | ||
野黄芩甙40 | 95.57±2.2 | ||
黄元5+野黄5 | 71.65±2.3 | 0.65 | |
黄元10+野黄10 | 89.7±2.2 | 0.75 | |
黄元20+野黄20 | 96.5±2.5 | 0.917 | |
黄元40+野黄40 | 99±2 | 1 | |
黄元2.5+野黄5 | 61.8±2 | 0.62 | |
黄元5+野黄10 | 85.7±3.5 | 0.7 | |
黄元10+野黄20 | 95±2.5 | 0.8 | |
黄元20+野黄40 | 98.2±2.1 | 1 | |
黄元2.5+野黄10 | 72.8±2.1 | 0.867 | |
黄元5+野黄20 | 92.5±2.1 | 0.88 | |
黄元10+野黄40 | 97.2±1.7 | 1.1 | |
黄元20+野黄80 | 99.5±2 | 1 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 7.2±5 | ||
黄元5 | 22.8±6 | ||
黄元10 | 50.9±5 | ||
黄元20 | 69.9±5 | ||
黄元40 | 92.9±7 | ||
野黄芩甙2.5 | 2±5 | ||
野黄芩甙5 | 18±3 | ||
野黄芩甙10 | 39±7 |
野黄芩甙20 | 72±9 | ||
野黄芩甙40 | 91.8±5 | ||
黄元5+野黄5 | 58±3.9 | 0.74 | |
黄元10+野黄10 | 79±5 | 0.89 | |
黄元20+野黄20 | 91±5 | 1 | |
黄元40+野黄40 | 98±7 | 0.96 | |
黄元2.5+野黄5 | 52±3 | 0.61 | |
黄元5+野黄10 | 69±5 | 0.858 | |
黄元10+野黄20 | 87±5 | 0.99 | |
黄元20+野黄40 | 97±3 | 0.91 | |
黄元2.5+野黄10 | 72±3 | 0.65 | |
黄元5+野黄20 | 82.8±5 | 0.97 | |
黄元10+野黄40 | 95±3 | 1 | |
黄元20+野黄80 | 99±5 | 0.91 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
黄元2.5 | 7.5±2.7 | ||
黄元5 | 22.7±2.2 | ||
黄元10 | 41.8±2.7 | ||
黄元20 | 60.6±3.2 | ||
黄元40 | 89.18±2.1 | ||
野黄芩甙2.5 | 2.25±2.7 | ||
野黄芩甙5 | 8.64±3.2 | ||
野黄芩甙10 | 37±2.2 | ||
野黄芩甙20 | 64.2±2.7 | ||
野黄芩甙40 | 88.5±2.5 | ||
黄元5+野黄5 | 52.02±2 | 0.743 | |
黄元10+野黄10 | 72.2±2.3 | 0.88 |
黄元20+野黄20 | 89.6±2 | 0.87 | |
黄元40+野黄40 | 95.82.2 | 0.97 | |
黄元2.5+野黄5 | 18±2.7 | 1.38 | |
黄元5+野黄10 | 69.3±2.7 | 0.72 | |
黄元10+野黄20 | 82.3±3.2 | 0.94 | |
黄元20+野黄40 | 95.7±2.5 | 0.76 | |
黄元2.5+野黄10 | 58±3 | 0.78 | |
黄元5+野黄20 | 77±2.1 | 0.95 | |
黄元10+野黄40 | 92.2±2.3 | 0.928 | |
黄元20+野黄80 | 98.1±3 | 0.8 |
分组 | 剂量mg/kg | 给药日程 | 体重减少率% | 瘤重(g)均值±SD, | 抑瘤率% | 动物数(只)始/末 |
对照组黄元野黄甙野黄甙野黄甙 | -302550100 | 腹腔1-10腹腔1-10腹腔1-10腹腔1-10 | <0<5<5<5<5 | 2.18±0.151.72±0.091.81±0.111.72±0.081.48±0.12 | 21.11721.132.1 | 10/1010/1010/1010/1010/10 |
野黄甙黄元+野黄甙黄元+野黄甙黄元+野黄甙黄元+野黄甙5-氟脲嘧啶 | 20030+2530+5030+10030+20010 | 腹腔1-10各腹腔1-10各腹腔1-10各腹腔1-10各腹腔1-10皮下1-10 | <5<5<5<5<5<5 | 1.22±0.091.62±0.081.51±0.121.2±0.091.07±0.081.35±0.1 | 4424.3*#30.7**#45**#51**#38 | 10/1010/1010/1010/1010/1010/10 |
分组 | 剂量mg/kg | 给药日程 | ILS(%) | 动物数(只)始/末 |
对照组黄元野黄甙野黄甙野黄甙野黄甙黄元+野黄甙黄元+野黄甙黄元+野黄甙黄元+野黄甙5-氟脲嘧啶 | -30255010020030+2530+5030+10030+20010 | 腹腔1-10腹腔1-10腹腔1-10腹腔1-10腹腔1-10各腹腔1-10各腹腔1-10各腹腔1-10各腹腔1-10腹腔1-10 | 31.611.926375136*#50**#53.7**#64.8**#79 | 10/1010/1010/1010/1010/1010/1010/1010/1010/1010/1010/10 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100065552A CN100508986C (zh) | 2005-02-01 | 2006-01-16 | 抗肿瘤的黄芩甙元和黄芩甙协同药物组合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510023724 CN1679604A (zh) | 2005-02-01 | 2005-02-01 | 抗肿瘤的协同药物组合物 |
CN200510023724.9 | 2005-02-01 | ||
CN200510025554.8 | 2005-04-29 | ||
CNB2006100065552A CN100508986C (zh) | 2005-02-01 | 2006-01-16 | 抗肿瘤的黄芩甙元和黄芩甙协同药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1839865A true CN1839865A (zh) | 2006-10-04 |
CN100508986C CN100508986C (zh) | 2009-07-08 |
Family
ID=37029169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100065552A Expired - Fee Related CN100508986C (zh) | 2005-02-01 | 2006-01-16 | 抗肿瘤的黄芩甙元和黄芩甙协同药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100508986C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104124A1 (fr) * | 2007-02-27 | 2008-09-04 | Aixian Qiao | Procédé de criblage de produits pharmaceutiques combinés, produits pharmaceutiques obtenus par le procédé et leurs utilisations |
CN102636626A (zh) * | 2008-02-26 | 2012-08-15 | 程宇镳 | 一种复方药物筛选方法,获得的药物及其应用 |
CN104586873A (zh) * | 2015-01-28 | 2015-05-06 | 苏州大学 | 木蝴蝶苷a在制备治疗癌症药物中的应用 |
CN113952351A (zh) * | 2021-09-08 | 2022-01-21 | 隋新兵 | 用于治疗癌症的药物组合物及其制备方法和用途 |
-
2006
- 2006-01-16 CN CNB2006100065552A patent/CN100508986C/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104124A1 (fr) * | 2007-02-27 | 2008-09-04 | Aixian Qiao | Procédé de criblage de produits pharmaceutiques combinés, produits pharmaceutiques obtenus par le procédé et leurs utilisations |
CN102636626A (zh) * | 2008-02-26 | 2012-08-15 | 程宇镳 | 一种复方药物筛选方法,获得的药物及其应用 |
CN104586873A (zh) * | 2015-01-28 | 2015-05-06 | 苏州大学 | 木蝴蝶苷a在制备治疗癌症药物中的应用 |
CN104586873B (zh) * | 2015-01-28 | 2017-08-25 | 苏州大学 | 木蝴蝶苷a在制备治疗癌症药物中的应用 |
CN113952351A (zh) * | 2021-09-08 | 2022-01-21 | 隋新兵 | 用于治疗癌症的药物组合物及其制备方法和用途 |
CN113952351B (zh) * | 2021-09-08 | 2023-02-17 | 隋新兵 | 用于治疗癌症的药物组合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN100508986C (zh) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103282037B (zh) | 抗肿瘤生物碱的联合治疗 | |
CN101903028B (zh) | 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯 | |
CN1839865A (zh) | 抗肿瘤的黄芩甙元和黄芩甙协同药物组合物 | |
CN102552908A (zh) | 含青蒿素及青蒿素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
CN1679539A (zh) | 抗肿瘤的协同药物组合物 | |
JP2008528640A (ja) | バイカレインとバイカリンとの抗腫瘍相乗医薬組成物 | |
WO2008028336A1 (fr) | Composition pharmaceutique à base de scutellareine et de scutellarine ou de baicaline ayant un effet antitumoral synergique | |
CN1872049A (zh) | 野黄芩甙元与一种铂类化疗药物的联合 | |
CN101229175A (zh) | 一对原人参二醇衍生物和它们混合体的医药用途 | |
CN1691943A (zh) | 利用g6976及其相关化合物进行肿瘤治疗 | |
CN1875958A (zh) | 协同抗肿瘤的野黄芩甙元和黄芩甙药物组合物 | |
CN1679604A (zh) | 抗肿瘤的协同药物组合物 | |
CN110314149B (zh) | 一种聚普瑞锌片及其制备工艺 | |
CN1915232A (zh) | 黄岑甙元与一种铂类化疗药物的联合 | |
CN100443081C (zh) | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 | |
CN1879615B (zh) | 抗肿瘤的协同药物组合物 | |
CN101485665A (zh) | 葫芦素新的医药用途 | |
CN102440987B (zh) | 含有芹菜素及芹菜素类衍生物和青蒿素及青蒿素类衍生物的药物组合物及其应用 | |
CN101143141A (zh) | 黄芩甙元或野黄芩甙元与去氧氟尿苷的联合 | |
CN104447921A (zh) | 一种牛蒡子苷元-吉西他滨偶联物及其制备方法、医药用途 | |
KR20210150470A (ko) | A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용 | |
CN115089576B (zh) | 木犀草素和菊苣酸联合在制备乳腺癌治疗药物中的应用 | |
CN1771931A (zh) | 二萜类化合物在制备对化疗药物具有协同作用的药物中的用途 | |
CN1267093C (zh) | 黄芩甙元在制备抗肿瘤药物中的用途 | |
CN102526033B (zh) | 由表没食子儿茶素没食子酸酯与丝裂霉素c制成的抑制肿瘤细胞增殖的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090220 Address after: Room 1, building 1225, Shangcheng Road, 216, Shanghai, Pudong New Area: 200120 Applicant after: Shanghai Geluoli Biology Medicine Technology Co., Ltd. Address before: Room 1802, room 2, 700 lane, Wuyi Road, Shanghai, Changning District: 200051 Applicant before: Wu Yixin |
|
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI GELU AOLI BIO-MEDICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: WU YIXIN Effective date: 20090220 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090708 Termination date: 20140116 |